FDA Completes Review of Final Clinical Study of ENHANCE

share Share


Following two years of treatment, carotid artery thickness increased by 0.011 mm in the Vytorin group and by 0.006 mm in the simvastatin group. The difference in the changes in carotid artery thickness between the two groups was not statistically significant. However, the levels of LDL cholesterol decreased by 56% in the Vytorin group and decreased by 39% in the simvastatin group. The difference in the reductions in LDL cholesterol between the two groups was statistically significant.

The results from ENHANCE do not change FDA

«« Next Generation Diagnostic Tool May Transform Patient Outcomes


Study Proves Smoking Ban Effective »»

Published on : Mon, 12 Jan 2009


Following two years of treatment, carotid artery thickness increased by 0.011 mm in the Vytorin group and by 0.006 mm in the simvastatin group. The diffe

No comment


Please login to leave a comment...

Highlighted Products